Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.51 |
| ▸ | TK2 | O00142 | 4/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | TK1 | P04183 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16704789 | 0.95 | TK2 (0.46) | RNASE1TK2SLC6A2ABCG2ABCB1 | |
| SCHEMBL13963213 | 0.95 | TK2 (0.46) | RNASE1TK2SLC6A2ABCG2ABCB1 | |
| SCHEMBL13963223 | 0.87 | TK2 (0.39) | RNASE1TK2SLC6A2ABCG2ABCB1 | |
| SCHEMBL21078683 | 0.86 | RNASE1 (0.56) | RNASE1TK2SLC6A2TK1 | |
| SCHEMBL13963217 | 0.85 | TK2 (0.48) | RNASE1TK2SLC6A2ABCG2ABCB1 | |
| SCHEMBL8999382 | 0.84 | TK2 (0.67) | RNASE1TK2SLC6A2ABCG2ABCB1 | |
| SCHEMBL16573643 | 0.84 | RNASE1 (0.41) | RNASE1TK2SLC6A2ABCG2ABCB1 | |
| SCHEMBL16130869 | 0.84 | RNASE1 (0.41) | RNASE1TK2SLC6A2ABCG2ABCB1 | |
| SCHEMBL20518491 | 0.82 | TK2 (0.41) | RNASE1TK2ABCG2ABCB1TK1 | |
| SCHEMBL16349867 | 0.79 | RNASE1 (0.71) | RNASE1TK2SLC6A2ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4293035-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2023-12-20 | — | — | EP | disclosed |
| WO-2020196890-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATE SITE | 味の素株式会社 | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, NOX4, POLRMT | RNASE1 711/4885TK2 121/4885SLC6A2 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.